



UNIVERSITI PUTRA MALAYSIA

**PHYSICOCHEMICAL CHARACTERIZATION OF PALLADIUM-,
PLATINUM-, SILVER-DOPED MAGNESIA NANOPARTICLES AND *IN*
VITRO CYTOTOXICITY IN A549 (LUNG) AND HT29 (COLON) CANCER
CELL LINES**

MOHAMMED QASIM KHLAIF

IB 2019 18



**PHYSICOCHEMICAL CHARACTERIZATION OF PALLADIUM-,
PLATINUM-, SILVER-DOPED MAGNESIA NANOPARTICLES AND *IN*
VITRO CYTOTOXICITY IN A549 (LUNG) AND HT29 (COLON) CANCER
CELL LINES**

By

MOHAMMED QASIM KHLAIF

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfillment of the Requirements for the Degree of Doctor of Philosophy**

January 2019

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright© Universiti Putra Malaysia



DEDICATION

I wish to dedicate this thesis to my mother (Samerah Obaid) and father (Qasim K. Al-Fahdawi) for their love and giving me the genes for research. They have always believed in me and have always encouraged me not only during this PhD period but throughout life.



© COPYRIGHT UPM

Abstract of the thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Doctor of Philosophy

PHYSICOCHEMICAL CHARACTERIZATION OF PALLADIUM-, PLATINUM-, SILVER-DOPED MAGNESIA NANOPARTICLES AND *IN VITRO* CYTOTOXICITY IN A549 (LUNG) AND HT29 (COLON) CANCER CELL LINES

By

MOHAMMED QASIM KHLAIF

January 2019

Chairman : Professor Rasedee Abdullah, PhD
Faculty : Institute of Bioscience

Cancers are one of the main causes of death in the developed countries. Currently, there is ongoing search for innovative therapeutics and strategies to combat the disease. This study was conducted to prepare three noble metal complexes, namely, palladium-, platinum-, and silver-doped magnesia designated Pt/MgO, Pd/MgO, and Ag/MgO nanoparticles, respectively, and to determine their cytotoxic potentials. These nanoparticles were prepared by hydrothermal impregnation method followed by calcination. The chemical compositions, functional groups, and optical properties of these nanoparticles were determined using X-ray diffraction (XRD), thermal gravimetric analysis (TGA), Fourier transform infrared spectroscopy (FT-IR), and Brunner-Emmett-Teller (BET) surface area measurements. The sizes, size distribution, and morphology of nanoparticles have been determined by zetasizer. Transmission (TEM) and scanning electron (SEM) microscopy were also used to determine their ultrastructure and estimate the size of the nanoparticles. The cytotoxicity of these nanoparticles against the human colon (HT29) and lung cancer (A549), and normal human colon (CCD-18Co) and lung (MRC-5) cell lines was evaluated using the (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The caspase-3, -8 and -9, activities, and Bax, Bcl-2 and p53 protein expressions were also determined in cancer cells treated with Pt/MgO, Pd/MgO, and Ag/MgO nanoparticles.

The Pd/MgO, Pt/MgO, and Ag/MgO nanoparticles prepared in this study were pure and crystalline and cuboid in structure with physical and thermal stability. The size of these nanoparticle ranged from 30 to 80 nm. The Pt/MgO, Pd/MgO, and Ag/MgO were relative innocuous to normal cells. However, the nanoparticles variably induced apoptosis of HT29 and A549 cells via the caspase-3/7- and caspase-9-

dependent mitochondrial signaling pathway. The Pd/MgO nanoparticles did not induce receptor-mediated (extrinsic) apoptotic pathway in colon cancer HT29 cells. The Ag/MgO nanoparticles had least effect among nanoparticles on the cancer cell receptor-mediated apoptotic pathway. All three nanoparticles expressed pro-apoptotic Bcl-2 protein and induce anti-tumour effect through the activation of the tumour suppressor protein, p53.

In conclusion, Pt/MgO, Pd/MgO, and Ag/MgO nanoparticles have anti-colon and anti-lung cancer cell effects through the induction of apoptosis. All three metal-doped nanoparticles have potential to be developed into efficacious anti-cancer compounds.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**PENCIRIAN FISIKOKIMIA NANOZARAH MAGNESIA TERDOP
PALADIUM, PLATINUM, AND ARGENTUM DAN KETOKSOKIKAN *IN*
VITRO PADA TITISAN SEL KANSER A549 (PARU-PARU) DAN HT29
(KOLON)**

Oleh

MOHAMMED QASIM KHLAIF

Januari 2019

Pengerusi : Profesor Rasedee Abdullah, PhD
Faculty : Institut Biosains

Kanser adalah antara penyebab utama kematian di negara maju. Kini, banyak penyelidikan yang dijalankan untuk menemui terapeutik and strategi yang inovatif untuk rawatan penyakit ini. Kajian ini dijalankan untuk menyediakan tiga kompleks logam nobel, iaitu, nanozarah magnesia terdop paladium, platinum, dan argentum yang masing-masing dinamakan nanozarah Pd/MgO, Pt/MgO, dan Ag/MgO, dan untuk menentukan potensi kesitotoksikannya. Nanozarah ini disediakan mengguna kaedah impregnasi hidroterma diikuti dengan kalsinasi. Komposisi kimia, kumpulan fungsian, dan sifat optik nanozarah ini ditentukan melalui belauan sinar-X (XRD), analisis gravimetri terma (TGA), spektroskopi inframerah transformasi Fourier (FT-IR), dan sukatan kawasan permukaan Brunner-Emmett-Teller (BET). Saiz, taburan saiz, dan morfologi nanozarah ditentukan mengguna zetasizer. Mikroskopi elektron pancaran (TEM) and imbasan (SEM) juga diguna untuk menentukan ultrastruktur dan saiz nanozarah tersebut. Kesitoksikan nanozarah terhadap titisan sel kanser kolon (HT29) and paru-paru (A539), sel kolon (CCD-18Co) dan paru-paru (MRC-5) normal dinilai mengguna asai (4,5-dimetiltiazol-2-yl)-2,5-difenyitetrazolium bromida (MTT). Aktiviti kaspase-3, -8, -9, pernyataan protein Bax, Bcl-2, and p53 juga ditentukan pada sel kanser terperlaku nanozarah Pd/MgO, Pt/MgO, dan Ag/MgO.

Nanozarah Pd/MgO, Pt/MgO, dan Ag/MgO yang disediakan dalam kajian ini adalah murni dan berstruktur kristal and kuboid dan stabil fizikal dan terma. Saiz nanozarah adalah pada julat 30 hinggg 80 nm. Nanozarah Pd/MgO, Pt/MgO, dan Ag/MgO tidak memberi kesan buruk terhadap sel normal. Bagaimanapun, nanozarah secara berbeza mengaruh apoptosis pada sel HT29 dan A549 melalui laluan pengisyaratan mitokondrion bersandarkan kaspase-3/7 dan kaspase-9. Nanozarah Pd/MgO tidak mengaruh arah laluan apoptosis berantara reseptor (ekstrinsik) pada sel kanser kolon,

HT29. Di kalangan nanozarah ini, kesan Ag/MgO terhadap arah laluan apoptosis berantarkan reseptor sel kanser adalah yang paling kurang. Ketiga-tiga nanozarah ini menyatakan protein Bcl-2 dan mengaruh kesan anti-tumor melalui pengaktifan protein penindas tumor, p53.

Kesimpulan, nanozarah Pt/MgO, Pd/MgO, and Ag/MgO mempunyai kesan antikanser kolon dan paru-paru melalui pengaruh apoptosis. Ketiga-tiga nanozarah terdop logam ini berpotensi untuk dikembangkan sebagai sebatian antikanser yang mujarab.



ACKNOWLEDGEMENTS

In the Name of Allah, Most Gracious, Most Merciful, all praise and thanks are due to Allah, and peace and blessings be upon His Messenger. I would like to express the most sincere appreciation to those who made this work possible: Advisory members, Friends and Family.

I would like to thank Prof. Dr Rasedee Abdullah for providing me the opportunity to complete my PhD studies under his valuable guidance, for the many useful advice and discussions, for his constant encouragement and guidance, and for co-authoring and reviewing some of my publications, where his practical experience and technical knowledge made this research and those publications more interesting and relevant. In addition, special thanks extend to the supervisory committee member; Prof. Dr. Yun Hin Taufiq-Yap and Prof. Dr. Rozita Rosli. I am grateful for their willingness to serve on my supervisory committee, constant encouragement, helpful advice and many fruitful discussions.

Thanks and acknowledgements are meaningless if not extended to my dearest friend Mothanna Sadiq Obaid Al-Qubaisi who deserves my deepest appreciation. I am grateful for the countless sacrifices he made to ensure that I could pursue my dreams and for always being there for me. Real and deepest thanks to him (May ALLAH bless and protect him and may he live long and healthy life). All praise and thanks words said to him will not be enough.

Thank you.

This thesis submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee are as follows:

Rasedee Abdullah, PhD

Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Chairman)

Yun Hin Taufiq-Yap, PhD

Professor
Faculty of Science
Universiti Putra Malaysia
(Member)

Rozita Rosli, PhD

Professor
Faculty of Medicine and Health Science
Universiti Putra Malaysia
(Member)

ROBIAH BINTI YUNUS, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software

Signature: _____ Date: _____

Name and Matric No: Mohamed Q. Khlaif, GS47967

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) were adhered to.

Signature: _____

Name of

Chairman of

Supervisory Committee: Professor Dr. Rasedee Abdullah

Signature: _____

Name of

Member of

Supervisory Committee: Professor Dr. Yun Hin Taufiq-Yap

Signature: _____

Name of

Member of

Supervisory Committee: Professor Dr. Rozita Rosli

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	iii
ACKNOWLEDGEMENTS	v
APPROVAL	vi
DECLARATION	viii
LIST OF TABLES	xiv
LIST OF FIGURES	xv
LIST OF ABBREVIATIONS	xx
CHAPTER	
1 INTRODUCTION	1
1.1 Background	1
1.2 Problem Statement	1
1.3 Objectives	3
1.3.1 General objective:	3
1.3.2 Specific objectives:	3
1.4 Hypothesis	3
1.5 Limitation of study	3
2 LITERATURE REVIEW	4
2.1 Cancer	4
2.1.1 Background	4
2.1.2 Lung cancer	5
2.1.3 Colon cancer	6
2.2 Limitations of current cancer chemotherapy	7
2.3 Metal nanoparticles as therapeutic compounds	7
2.3.1 Noble metal-oxide	8
2.3.2 Targeting strategies for cancer	9
2.4 Physicochemical characterization of nanoparticles	10
2.4.1 X-ray diffraction	10
2.4.2 Fourier transform infrared spectrometer	13
2.4.3 Energy-dispersive X-ray spectroscopy	15
2.4.4 Thermal analysis	16
2.4.4.1 Thermogravimetric analysis	16
2.4.4.2 Differential scanning calorimetry	16
2.5 <i>In vitro</i> test	17
2.6 Apoptosis	18
2.6.1 Mediators of apoptosis	18
2.6.1.1 Caspases	18
2.6.1.2 Bcl-2 family	19
2.6.2 Apoptotic pathways	20
2.6.2.1 The intrinsic pathway	21
2.6.2.2 Extrinsic Pathway	21
2.7 Tumour suppressor p53 gene	22

3	MATERIALS AND METHODS	23
3.1	Chemicals and reagents	23
3.2	Preparation of nanoparticles	23
3.2.1	Preparation of Pt/MgO, Pd/MgO and Ag/MgO nanoparticles	23
3.3	Physicochemical properties of nanoparticles	24
3.3.1	Scanning electron microscopy and energy dispersive X-ray spectroscopy	24
3.3.2	Transmission electron microscopy	24
3.3.3	X-ray Diffraction	24
3.3.4	Fourier transform infrared	24
3.3.5	Thermogravimetric analysis	25
3.3.6	Brunauer, Emmett and Teller analysis	25
3.4	Cell Culture	25
3.5	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay	25
3.6	Caspases	26
3.7	Quantification of Bax, p53, Bcl-2 and cytochrome C protein assay	26
3.8	Microscopic examination of cell morphology	26
3.9	Statistical analysis	27
4	CYTOTOXICITY AND PHYSICOCHEMICAL CHARACTERIZATION OF PLATINUM-DOPED MAGNESIA NANOPARTICLES	28
4.1	Introduction	28
4.2	Materials and Methods	29
4.2.1	Preparation of platinum-doped magnesia nanoparticles	29
4.2.2	Scanning electron microscopy and energy dispersive X-ray spectroscopy	29
4.2.3	Transmission electron microscopy	29
4.2.4	X-ray diffraction	29
4.2.5	Fourier transform infrared	29
4.2.6	Thermogravimetric analysis	29
4.2.7	Brunauer, Emmett and Teller analysis	29
4.2.8	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay	30
4.2.9	Caspase assay	30
4.2.10	Bcl-2, Bax, P53, and cytochrome c protein assay	30
4.2.11	Microscopic cell morphology	30
4.3	Results	30
4.3.1	Characterization	30
4.3.1.1	Morphological and elemental analysis of nanoparticles	30
4.3.1.2	Crystallinity	34
4.3.1.3	Infrared absorption bands	35
4.3.1.4	Thermogravimetric analysis	36
4.3.2	Anticancer of Pt/MgO nanoparticles	37

4.3.2.1	Cytotoxicity	37
4.3.2.2	Caspase-3, -8 and -9	40
4.3.2.3	Bcl-2, Bax, p53 and cytochrome C proteins	43
4.3.2.4	Morphological examination	48
4.4	Discussion	49
4.5	Conclusion	50

5 CYTOTOXICITY AND PHYSICOCHEMICAL CHARACTERIZATION OF PALLADIUM-DOPED MAGNESIA NANOPARTICLES **51**

5.1	Introduction	51
5.2	Materials and Methods	52
5.2.1	Preparation of Pd/MgO nanoparticles	52
5.2.2	Scanning electron microscopy and energy dispersive X-ray spectroscopy	52
5.2.3	Transmission electron microscopy	52
5.2.4	X-ray diffraction	52
5.2.5	Fourier transform infrared	52
5.2.6	Thermogravimetric analysis	52
5.2.7	Brunauer, Emmett and Teller analysis	52
5.2.8	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay	52
5.2.9	Caspase assay	52
5.2.10	Bcl-2, Bax, P53, and cytochrome c protein assay	52
5.2.11	Microscopic cell morphology	53
5.3	Results	53
5.3.1	Characterization	53
5.3.1.1	Morphological and elemental analysis of nanoparticles	53
5.3.1.2	Determination of crystallinity	55
5.3.1.3	Infrared absorption	56
5.3.1.4	Thermogravimetric analysis	57
5.3.2	Anticancer effect of Pd/MgO nanoparticles	58
5.3.2.1	Cytotoxicity	58
5.3.2.2	Caspase-3, -8 and -9	62
5.3.2.3	Bcl-2, Bax, p53 and cytochrome C proteins	65
5.3.2.4	Morphological examination of treated cells	71
5.4	Discussion	72
5.5	Conclusion	73

6 CYTOTOXICITY AND PHYSICOCHEMICAL CHARACTERIZATION OF SILVER-DOPED MAGNESIA NANOPARTICLES **74**

6.1	Introduction	74
6.2	MATERIALS AND METHODS	75
6.2.1	Preparation of Ag/MgO nanoparticles	75

6.2.2	Scanning electron microscopy and energy dispersive X-ray spectroscopy	75
6.2.3	Transmission electron microscopy	75
6.2.4	X-ray diffraction	75
6.2.5	Fourier transform infrared	75
6.2.6	Thermogravimetric analysis	75
6.2.7	Brunauer, Emmett and Teller analysis	75
6.2.8	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay	75
6.2.9	Caspase assay	75
6.2.10	Bcl-2, Bax, P53, and cytochrome C protein assay	75
6.2.11	Microscopic cell morphology	76
6.3	Results	76
6.3.1	Characterization	76
6.3.1.1	Morphological and elemental analysis of nanoparticles	76
6.3.1.2	Crystallinity	78
6.3.1.3	Infrared absorption bands	79
6.3.1.4	Thermogravimetric analysis	80
6.3.2	Anticancer of Ag/MgO nanoparticles	81
6.3.2.1	Cytotoxicity	81
6.3.2.2	Caspase-3, -8 and -9	85
6.3.2.3	Morphological examination of treated cells	93
6.4	Discussion	94
6.5	Conclusion	96
7	GENERAL DISCUSSION, CONCLUSION AND RECOMMENDATION	97
7.1	Conclusion	99
7.2	Recommendation	99
	REFERENCES	100
	BIODATA OF STUDENT	125
	LIST OF PUBLICATIONS	126

LIST OF TABLES

Table		Page
4.1	IC ₅₀ values of Pt/MgO nanoparticles, oxalipatin, and paclitaxel on human normal colon (CCD-18Co) and cancer (HT29) cells and human normal lung (MRC-5) and cancer (A549) cells at 24 hours of treatment.	37
5.1	IC ₅₀ values of Pd/MgO nanoparticles, oxalipatin, and paclitaxel on human normal colon (CCD-18C0) and lung (MRC-5) lung, colon (HT29), and lung (A549) cancer cells at 24 hours.	59
6.1	IC ₅₀ values of Ag/MgO nanoparticles, oxalipatin, and paclitaxel on human normal colon (CCD-18C0) and lung (MRC-5) lung, colon (HT29), and lung (A549) cancer cells at 24 hours.	82

LIST OF FIGURES

Figure		Page
2.1	Hallmarks of cancer	5
2.2	X-ray analysis of crystalline substances	11
2.3	Debye cone	12
2.4	Schematic illustration of the principle of Attenuated Total Reflection technique.	14
2.5	A typical setup of energy-dispersive X-ray spectroscopy.	15
2.6	Thermobalance in thermogravimetric analysis	17
2.7	Apoptosis pathways	20
4.1	Scanning ultramicroscopic structure of pure Pt/MgO nanoparticles.	31
4.2	Energy dispersive X-ray spectroscopy of pure Pt/MgO nanoparticles.	32
4.3	Transmission ultramicroscopic structure of pure Pt/MgO nanoparticles.	33
4.4	X-ray diffraction (XRD) pattern of Pt/MgO nanoparticles. The data confirms the formation of nanoparticles, its definitive structural, and phase purity identification of Pt/MgO.	34
4.5	Fourier transform infrared spectrum of Pt/MgO nanoparticles.	35
4.6	Thermograph of the Pt/MgO nanoparticle sample. Phase purity analysis of samples through thermal treatments was confirmed by the thermogravimetric analysis.	36
4.7a	Effect of Pt/MgO nanoparticles and chemotherapeutics on the viability of cells determined by through mitochondrial activity using the 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. HT29 = Human colorectal adenocarcinoma cell line; A549 = Human breast adenocarcinoma.	38
4.7b	Effect of Pt/MgO nanoparticles and chemotherapeutics on the viability of cells determined by through mitochondrial activity using the 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. CCD-18Co = human normal colon cell line; MRC-5 = human normal pulmonary embryonic fibroblasts.	39
4.8	Effect Pt/MgO nanoparticles on caspase-3 activities of human colorectal adenocarcinoma (HT29) and lung adenocarcinoma (A549)	

	cell lines at 12 and 24 hours of exposure. Zero concentration are the nontreated cells.	40
4.9	Effect Pt/MgO nanoparticles on caspase-8 activities of human colorectal adenocarcinoma (HT29) and lung adenocarcinoma (A549) cell lines at 12 and 24 hours of exposure. Zero concentration are the nontreated cells.	41
4.10	Effect Pt/MgO nanoparticles on caspase-9 activities of human colorectal adenocarcinoma (HT29) and lung adenocarcinoma (A549) cell lines at 12 and 24 hours of exposure. Zero concentration are the nontreated cells.	42
4.11	Effect Pt/MgO nanoparticles on Bcl-2 protein expression by human colorectal adenocarcinoma (HT29) and lung adenocarcinoma (A549) cell lines at 12 and 24 hours of exposure. Zero concentration are the nontreated cells.	44
4.12	Effect Pt/MgO nanoparticles on Bax protein expression by human colorectal adenocarcinoma (HT29) and lung adenocarcinoma (A549) cell lines at 12 and 24 hours of exposure. Zero concentration are the nontreated cells.	45
4.13	Effect Pt/MgO nanoparticles on p53 protein expression by human colorectal adenocarcinoma (HT29) and lung adenocarcinoma (A549) cell lines at 12 and 24 hours of exposure. Zero concentration are the nontreated cells.	46
4.14	Effect Pt/MgO nanoparticles on cytochrome C release by human colorectal adenocarcinoma (HT29) and lung adenocarcinoma (A549) cell lines at 12 and 24 hours of exposure. Zero concentration are the nontreated cells.	47
4.15	Effect of treatment with IC ₅₀ concentration of Pt/MgO nanoparticles on the human colorectal adenocarcinoma (HT29) and lung adenocarcinoma (A549) cell lines after 24 hour. Black arrows indicate apoptotic cells with typical membrane blebbing. The apoptotic cells showed the characteristic morphological features, including loss of membrane asymmetry and cell shrinkage. Light microscope (200×).	48
5.1	Scanning electron micrograph of pure Pd/MgO nanoparticles. The nanoparticles were well dispersed and sizes ranged from 44 to 85 nm. The nanoparticles are cuboid.	53
5.2	Energy dispersive X-ray spectroscopy of pure Pd/MgO nanoparticles. Cross-sectional SEM-EDX mapping demonstrating that the composition of the fine-grain layer resulting from the powdering of Pd/MgO nanoparticle is mostly comprised of Pd/MgO with no signal	

	from pure Pd alone or, MgO alone. Thus, the original raw materials are absent in the final produced nanoparticle.	54
5.3	Transmission electron microscopy of pure Pd/MgO nanoparticles.	55
5.4	XRD pattern of Pd/MgO nanoparticles. The pattern supports the formation of Pd/mgO nanoparticles, and the definitive structural and phase purity identification of Pd/MgO.	56
5.5	FT-IR spectrum of Pd/MgO nanoparticles.	57
5.6	Thermogravimetric analysis (TGA) of Pd/MgO nanoparticles. The TGA analysis confirmed the phase purity samples through thermal treatment.	58
5.7a	Effect of Pd/MgO nanoparticles and chemotherapeutics on the viability of cells determined by through mitochondrial activity using the 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. HT29 = Human colorectal adenocarcinoma cell line; A549 = Human breast adenocarcinoma.	60
5.7b	Effect of Pd/MgO nanoparticles and chemotherapeutics on the viability of cells determined by through mitochondrial activity using the 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. CCD-18Co = human normal colon cell line; MRC-5 = human normal pulmonary embryonic fibroblasts.	61
5.8	Effect of treatment with Pd/MgO nanoparticles on the caspase-3 activities of the human colon (HT29) and lung (A549) adenocarcinoma cells.	62
5.9	Effect of treatment with Pd/MgO nanoparticles on the caspase-8 activities of the human colon (HT29) and lung (A549) adenocarcinoma cells	63
5.10	Effect of treatment with Pd/MgO nanoparticles on the caspase-9 activities of the human colon (HT29) and lung (A549) adenocarcinoma cells.	64
5.11	Effect of treatment with Pd/MgO nanoparticles on Bcl-2 protein expression in the human colon (HT29) and lung (A549) adenocarcinoma cells.	66
5.12	Effect of treatment with Pd/MgO nanoparticles on Bax protein expression in the human colon (HT29) and lung (A549) adenocarcinoma cells.	67
5.13	Effect of treatment with Pd/MgO nanoparticles on p53 protein expression in the human colon (HT29) and lung (A549) adenocarcinoma cells.	69

5.14	Effect of treatment with Pd/MgO nanoparticles on cytochrome C expression in the human colon (HT29) and lung (A549) adenocarcinoma cells.	70
5.15	Effect of treatment with IC ₅₀ concentration of Pd/MgO nanoparticles on human colon (HT29) and lung (A549) adenocarcinoma cell morphology. Black arrows indicate apoptotic cells with typical membrane blebbing. The apoptotic process has characteristic morphological features, including loss of membrane asymmetry and cell shrinkage. Light microscope (magnification, 200×).	71
6.1	Scanning electron micrograph of pure Ag/MgO nanoparticles. The nanoparticles were well dispersed and sizes ranged from 36 to 68 nm	76
6.2	Energy dispersive X-ray spectroscopy of pure Ag/MgO nanoparticles. Cross-sectional SEM-EDX mapping demonstrating that the composition of the fine-grain layer resulting from the powdering of Ag/MgO nanoparticle is mostly comprised of Ag/MgO with no signal from pure Ag or MgO alone. Thus, the original raw materials are absent in the final produced nanoparticle.	77
6.3	Transmission electron microscopy of pure Ag/MgO nanoparticles. Most nanoparticles are agglomerated.	78
6.4	X-ray diffraction (XRD) pattern of Ag/MgO nanoparticles. It supports the formation of nanoparticles, a definitive structural and phase purity identification of Ag/MgO.	79
6.5	FT-IR spectrum of Ag/MgO nanoparticles.	80
6.6	Thermograph of the Ag/MgO nanoparticles sample.	81
6.7a	Effect of Ag/MgO nanoparticles and chemotherapeutics on the viability of cells determined by through mitochondrial activity using the 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. HT29 = Human colorectal adenocarcinoma cell line; A549 = Human breast adenocarcinoma.	83
6.7b	Effect of Ag/MgO nanoparticles and chemotherapeutics on the viability of cells determined by through mitochondrial activity using the 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. CCD-18Co = human normal colon cell line; MRC-5 = human normal pulmonary embryonic fibroblasts.	84
6.8	Effect of treatment with Ag/MgO nanoparticles, at different concentrations (3.125, 6.25, and 12.5 µg/ml) for 12 and 24 hours, on the caspase-3 activity in cell lines. HT29 = Human colorectal adenocarcinoma cell line; A549 = human lung adenocarcinoma cell line.	85

- 6.9 Effect of treatment with Ag/MgO nanoparticles, at different concentrations (3.125, 6.25, and 12.5 $\mu\text{g/ml}$) for 12 and 24 hours, on the caspase-8 activity in cell lines. HT29 = Human colorectal adenocarcinoma cell line; A549 = human lung adenocarcinoma cell line. 86
- 6.10 Effect of treatment with Ag/MgO nanoparticles, at different concentrations (3.125, 6.25, and 12.5 $\mu\text{g/ml}$) for 12 and 24 hours, on the caspase-9 activity in cell lines. HT29 = Human colorectal adenocarcinoma cell line; A549 = human lung adenocarcinoma cell line. 87
- 6.11 Effect of treatment with Ag/MgO on Bcl-2 protein level in HT29, and A549 cells. The Bcl-2 protein levels are shown as the relative ratios for nanoparticle-treated cells to that of nontreated cells. Mean \pm standard deviation (n = 3 wells/treatment). *P < 0.05 compared with nontreated cells. 89
- 6.12 Effect of treatment with Ag/MgO on Bax protein level in HT29, and A549 cells. The Bax protein levels are shown as the relative ratios for nanoparticle-treated cells to that of nontreated cells. Mean \pm standard deviation (n = 3 wells/treatment). *P < 0.05 compared with nontreated cells. 90
- 6.13 Effect of treatment with Ag/MgO on p53 level in HT29 and A549 cells. The Bcl-2 protein levels are shown as the relative ratios for nanoparticle-treated cells to that of nontreated cells. Mean \pm standard deviation (n = 3 wells/treatment). *P < 0.05 compared with nontreated cells. 91
- 6.14 Effect of treatment with Ag/MgO on cytochrome C protein level in HT29, and A549 cells. The amount of released cytochrome C is shown as the relative ratio for nanoparticle-treated cells to that of nontreated cells. Mean \pm standard deviation (n = 3 wells/treatment). *P < 0.05 compared with nontreated cells. 92
- 6.15 Effect of treatment with Ag/MgO nanoparticles at their respective 24-hour IC_{50} concentrations on cell morphology. HT29 = Human colorectal adenocarcinoma cell line; A549 = Human lung adenocarcinoma cell line. Black arrows indicate apoptotic cells with typical membrane blebbing. Light microscope (200 \times). 93

LIST OF ABBREVIATIONS

ATCC	The American Type Culture Collection
CO ₂	Carbon dioxide
DMEM	Dulbecco's modified Eagle's medium
DMSO	Dimethyl sulphoxide
DTT	Dithiothreitol
dUTP	2'-deoxyuridine 5'-triphosphate
EDTA	Ethylendiaminetetraacetic acid
ELISA	Enzyme-linked Immunosorbent Assay
EtOH	Ethanol
FBS	Fetal bovine serum
XRD	X-ray diffraction
TGA	Thermogravimetric analysis
FTIR	Fourier transform infrared
TEM	Transmission electron microscopy
HCl	Hydrochloric acid
IC ₅₀	Inhibition concentration at 50 percent
KCl	Potassium Chloride
KH ₂ PO ₄	Potassium dihydrogen phosphate
LDH	Lactate Dehydrogenase
BET	Brunauer, Emmett and Teller analysis
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NaCl	Sodium Chloride
NADH	Nicotinamide adenine dinucleotide
NaHPO ₄	Disodium hydrogen phosphate anhydrous

NaOH	Sodium hydroxide
PBS	Phosphate buffer saline
A549	Human lung cancer cell line
HT29	Human colorectal adenocarcinoma cell line
CCD-18Co	Human normal colon cell line
MRC-5	Human normal lung cell line



CHAPTER 1

INTRODUCTION

1.1 Background

Cancer, or malignant tumour, is a disease caused by abnormal cell growth (Daniel *et al.*, 2001, Colditz and Stein, 2004, Jaggi, 2005). Excessive proliferation of tissue cells will eventually damage neighbouring healthy cells with lethal outcomes (Srivastava *et al.*, 1999). Cancer is one of the deadliest and most complicated diseases in medicine (Badve and Gökmen-Polar, 2016, Loda *et al.*, 2016, Dagleish and Browning, 1996) and it is the result of mutations in DNA responsible for the synthesis of cellular proteins (Knowles and Selby, 2005, Yousef and Jothy, 2014, Franks and Teich, 1997). In cancer, DNA abnormalities result in normal production of proteins (Ruddon, 2010), which are harmful to the organism (Pecorino, 2012, Macdonald *et al.*, 2004).

Colon cancer is the third most common cancer worldwide, accounting for over 9% of all cancer incidences (Hagggar and Boushey, 2009). In Malaysia, it is the second most common type of tumour accounting for 14.1% of all malignant tumours in men and 10.2% in women (Hagggar and Boushey, 2009). Recently bowel screening was introduced by the International Agency for Research on Cancer for people in the high risk age group of 60 to 69 years, to aid early detection of tumours and increase survivality (Cancer, 2012).

Lung tumours are largely a disease of the elderly, where almost 70% of sufferers were more than 65 years old (Siegel *et al.*, 2013). Approximately 90% of lung tumours are due long-term tobacco usage. Patients with lung cancers survives better if the cancer is detected early (Siegel *et al.*, 2016).

1.2 Problem Statement

The current first-line lung cancer therapies use cisplatin and gemcitabine (Macbeth *et al.*, 1996). Cisplatin induces its anticancer effects by forming DNA adducts and subsequently activating apoptotic pathways via p53. Sometimes, pemetrexed is used in combination with cisplatin for first-line therapy (Reckamp, 2016). However, treatment with cisplatin is plagued with reduced drug uptake, drug inactivation, and increased DNA damage.

Treatment of colon cancers is traditionally with surgery, radiotherapy, and chemotherapy (Baxter, 2014). Chemotherapeutic agents are used following surgery if there is evidence of spread of the tumour to neighbouring lymph nodes or features suggestive of cancer spread (Saltz, 2007). Among chemotherapeutics that have been

used in the last 10 years include Oxaliplatin, Irinotecan, anti-epidermal growth factor receptor agents such as Cetuximab in select patients, Bevacizumab, Aflibercept and Regorafenib, and Fluorouracil (Skeel and Khleif, 2011).

Cancer chemotherapy may be applied intravenously or orally (Skeel and Khleif, 2011). Chemotherapeutic drugs targets actively dividing cells causing side effects (Chu and DeVita, 2006, Doroshow, 2006). These side effects are dependent of the type, dose, and duration of the drug therapy. Among side effects of chemotherapies are mouth sores, nausea, diarrhoea, susceptibility to infection, bruising, loss of appetite, bleeding, hair loss, and vomiting (Perry, 2008). For these reasons, there is ongoing search for more selective anticancer drugs with minimal side effects (Seddon and Workman, 2014).

Among new strategies employed in the development of new therapeutic regimen is nanotechnology and nanomedicine (Jain *et al.*, 2014). Nanomedicine is a rapidly evolving field with the objective to improve disease treatment outcomes by enhancing diagnostic procedures and treatments (Jain, 2017, Tibbals, 2017). Nanomedicine refers to the use nanoscale materials to improve human health and well-being (Prasad, 2012). Nanoparticles with loaded or entrapped therapeutic agents have the characteristics of prolonged circulation time (Duzgunes, 2012), increased tissue targeting and uptake (Mishra, 2013), and decreased toxicity (Pan, 2014).

Due to their unique chemical and physical properties, noble metals such as gold, silver, palladium and platinum are now being investigated for their potential in diagnostic and therapeutic applications in cancers. Noble metals based-nanoparticles are easier and more convenient to engineer than non-metal drug carriers. The noble metal nanoparticles can be engineered to exhibit multifunctional or synergistic effects in the treatment of diseases (Jain *et al.*, 2008, Giljohann *et al.*, 2010, Bijur *et al.*, 2001). Noble metal-containing nanoparticles also have fewer side effects and cheaper to produce than currently available chemotherapeutic compounds (Merchant, 1998, Conde *et al.*, 2012).

In this study, three noble metals-based nanoparticles, palladium-doped (Pd/MgO), platinum-doped (Pt/MgO), and silver-doped magnesia (Ag/MgO) nanoparticles were developed as potential anticancer compounds. The anticancer properties of these nanoparticles were determined on the human colorectal adenocarcinoma (HT29), and lung adenocarcinoma (A549) cells. Application of these nanoparticles as chemotherapeutic agents are governed by the following: suitability of hydrothermal impregnation method in the synthesis of noble metals-containing nanoparticles, cytotoxicity towards cancer cells, selectivity of the nanoparticles for cancer cell lines, and the death pathway by which the nanoparticles exert their actions.

1.3 Objectives

1.3.1 General objective:

To prepare, physicochemically characterise and determine the anticancer cell effects of Pt/MgO, Pd/MgO, and Ag/MgO nanoparticles.

1.3.2 Specific objectives:

The specific objectives of the study are to

1. synthesize and characterise the physiochemical properties of, Pt/MgO, Pd/MgO, and Ag/MgO nanoparticles,
2. determine the *in vitro* cytotoxicity of Pt/MgO, Pd/MgO, and Ag/MgO nanoparticles on human colon cancer (HT29) and lung cancer (A549) cell lines,
3. determine the *in vitro* effect of apoptotic pathway markers in HT29 and A549 after treatment with Pt/MgO, Pd/MgO, and Ag/MgO nanoparticles.

1.4 Hypothesis

Based on existing literature, we hypothesise that palladium-, platinum-, and silver-doped magnesia are both thermal-stable and nanoparticulated. These nanoparticles will serve as potent chemo-preventative agents towards lung and colon cancer development. The anticancer effect of the magnesia-doped nanoparticles on lung and colon cancers is postulated to occur through the induction of oxidative stress and apoptosis.

1.5 Limitation of study

One obvious limitation of this study was the use absence of an animal model to confirm the anticancer effects of noble metal-doped magnesia in *in situ* tumour. In addition, in the study the molecular anticancer mechanisms of the nanoparticles were only superficially investigated. This limits the ability to conclude on the potential of the nanoparticles as anticancer agents.

Further research is needed to determine the effect the nanoparticles in combination chemotherapies. There is also need to determine the effect of noble metal doped magnesias on other cancers besides colon and lung cancers.

REFERENCES

- Acton, Q. A. 2012. Caspases—Advances in Research and Application: 2012 Edition: ScholarlyBrief Ed.: Scholarly Editions.
- Acton, Q. A. 2013. Adenocarcinomas: New Insights for the Healthcare Professional: 2013 Edition Ed.: Scholarly Editions.
- Acton, Q. A. 2013. Effector Caspases—Advances in Research and Application: 2013 Edition: ScholarlyBrief Ed.: Scholarly Editions.
- Acton, Q. A. 2013. Lung Cancer: New Insights for the Healthcare Professional: 2013 Edition Ed.: ScholarlyEditions.
- Agotegaray, M. A. & V. L. Lassalle. 2017. Silica-coated Magnetic Nanoparticles: An Insight into Targeted Drug Delivery and Toxicology Ed.: Springer International Publishing.
- Ahmad, A. 2016. Introduction to Cancer Metastasis Ed.: Elsevier Science.
- Ahmad, A. & S. Gadgeel. 2015. Lung Cancer and Personalized Medicine: Current Knowledge and Therapies Ed.: Springer International Publishing.
- Aioub, M., S. R. Panikkanvalappil & M. A. El-Sayed 2017. Platinum-coated gold nanorods: Efficient reactive oxygen scavengers that prevent oxidative damage toward healthy, untreated cells during plasmonic photothermal therapy. *ACS Nano* **11**(1): 579-586.
- Aird, R., J. Cummings, A. Ritchie, M. Muir, R. Morris, H. Chen, P. Sadler & D. Jodrell 2002. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. *British Journal of Cancer* **86**(10): 1652.
- Airley, R. 2009. Cancer Chemotherapy: Basic Science to the Clinic Ed.: Wiley.
- Al-Doghachi, F. A., U. Rashid & Y. H. Taufiq-Yap 2016. Investigation of Ce (III) promoter effects on the tri-metallic Pt, Pd, Ni/MgO catalyst in dry-reforming of methane. *RSC Advances* **6**(13): 10372-10384.
- Al-Doghachi, F. A., U. Rashid, Z. Zainal, M. I. Saiman & Y. H. T. Yap 2015. Influence of Ce₂O₃ and CeO₂ promoters on Pd/MgO catalysts in the dry-reforming of methane. *RSC Advances* **5**(99): 81739-81752.
- Al-Doghachi, F. J., Z. Zainal, M. I. Saiman, Z. Embong & Y. H. Taufiq-Yap 2015. Hydrogen production from dry-reforming of biogas over Pt/Mg_{1-x}Ni_xO catalysts. *Energy Procedia* **79**: 18-25.
- Al-Doghachi, F. J. A. 2018. Effects of Platinum and Palladium Metals on Ni/Mg_{1-x}Zr_xO Catalysts in the CO₂ Reforming of Methane. *Bulletin of Chemical Reaction Engineering & Catalysis* **13**(2): 295-310.

- Al-Qubaisi, M. S., A. Rasedee, M. H. Flaifel, S. H. Ahmad, S. Hussein-Al-Ali, M. Z. Hussein, Z. Zainal, F. H. Alhassan, Y. H. Taufiq-Yap & E. E. Eid 2013. Induction of apoptosis in cancer cells by NiZn ferrite nanoparticles through mitochondrial cytochrome C release. *International Journal of Nanomedicine* **8**: 4115.
- Alhassan, F. H., U. Rashid, M. S. AL-Qubaisi, A. Rasedee & Y. H. Taufiq-Yap 2014. The effect of sulphate contents on the surface properties of iron-manganese doped sulphated zirconia catalysts. *Powder Technology*.
- Ali, N. 2014. *Understanding Lung Cancer: An Introduction for Patients and Caregivers* Ed.: Rowman & Littlefield Publishers.
- Allen, D. & M. D. Waters. 2013. *Reducing, Refining and Replacing the Use of Animals in Toxicity Testing* Ed.: Royal Society of Chemistry.
- Amara, D., I. Felner, I. Nowik & S. Margel 2009. Synthesis and characterization of Fe and Fe₃O₄ nanoparticles by thermal decomposition of triiron dodecacarbonyl. *Colloids and Surfaces A: Physicochemical and Engineering Aspects* **339**(1): 106-110.
- Amiji, M. M. 2006. *Nanotechnology for Cancer Therapy* Ed.: CRC Press.
- André, T., C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. Topham, M. Zaninelli, P. Clingan & J. Bridgewater 2004. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *New England Journal of Medicine* **350**(23): 2343-2351.
- Andreeff, M. 2014. *Targeted Therapy of Acute Myeloid Leukemia* Ed.: Springer New York.
- Andronescu, E. & A. M. Grumezescu. 2017. *Nanostructures for Drug Delivery* Ed.: Elsevier Science.
- Ankamwar, B., C. Damle, A. Ahmad & M. Sastry 2005. Biosynthesis of gold and silver nanoparticles using *Emblica officinalis* fruit extract, their phase transfer and transmetallation in an organic solution. *Journal of Nanoscience and Nanotechnology* **5**(10): 1665-1671.
- Ansar, S. M., F. S. Ameer, W. Hu, S. Zou, C. U. Pittman Jr & D. Zhang 2013. Removal of molecular adsorbates on gold nanoparticles using sodium borohydride in water. *Nano Letters* **13**(3): 1226-1229.
- Argiris, A. 2012. *Lung Cancer* Ed.: Springer Publishing Company.
- Arvizo, R. R., S. Bhattacharyya, R. A. Kudgus, K. Giri, R. Bhattacharya & P. Mukherjee 2012. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. *Chemical Society Reviews* **41**(7): 2943-2970.

- Austin, L. A., B. Kang, C.-W. Yen & M. A. El-Sayed 2011. Plasmonic imaging of human oral cancer cell communities during programmed cell death by nuclear-targeting silver nanoparticles. *Journal of the American Chemical Society* **133**(44): 17594-17597.
- Badve, S. & Y. Gökmen-Polar. 2016. *Molecular Pathology of Breast Cancer* Ed.: Springer International Publishing.
- Bajpai, A., S. Shukla & R. Saini. 2010. *Stimuli Responsive Drug Delivery Systems: From Introduction to Application* Ed.: iSmithers.
- Baluk, P., H. Hashizume & D. M. McDonald 2005. Cellular abnormalities of blood vessels as targets in cancer. *Current Opinion in Genetics & Development* **15**(1): 102-111.
- Barile, F. A. 1994. *Introduction to In Vitro Cytotoxicology Mechanisms and Methods* Ed.: CRC Press.
- Baxter, N. 2014. *Treatment of Colorectal Cancer, An Issue of Surgical Oncology Clinics of North America*, E-Book Ed.: Elsevier Health Sciences.
- Bell, D. & A. Garratt-Reed. 2003. *Energy Dispersive X-ray Analysis in the Electron Microscope* Ed.: Taylor & Francis.
- Bendale, Y., V. Bendale & S. Paul 2017. Evaluation of cytotoxic activity of platinum nanoparticles against normal and cancer cells and its anticancer potential through induction of apoptosis. *Integrative medicine research* **6**(2): 141-148.
- Berthomieu, C. & R. Hienerwadel 2009. Fourier transform infrared (FTIR) spectroscopy. *Photosynthesis Research* **101**(2-3): 157-170.
- Bertrand, N., J. Wu, X. Xu, N. Kamaly & O. C. Farokhzad 2014. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. *Advanced Drug Delivery Reviews* **66**: 2-25.
- Bignold, L. P. 2006. *Cancer: Cell Structures, Carcinogens and Genomic Instability* Ed.: Birkhäuser Basel.
- Bijur, P. E., W. Silver & E. J. Gallagher 2001. Reliability of the visual analog scale for measurement of acute pain. *Academic Emergency Medicine* **8**(12): 1153-1157.
- Boca, S. C., M. Potara, A.-M. Gabudean, A. Juhem, P. L. Baldeck & S. Astilean 2011. Chitosan-coated triangular silver nanoparticles as a novel class of biocompatible, highly effective photothermal transducers for in vitro cancer cell therapy. *Cancer Letters* **311**(2): 131-140.
- Boelsterli, U. A. 2007. *Mechanistic Toxicology: The Molecular Basis of How Chemicals Disrupt Biological Targets*, Second Edition Ed.: Taylor & Francis.

- Boole, D. D. & D. W. Cho. 2007. Focus on Cell Apoptosis Research Ed.: Nova Science.
- Brannon-Peppas, L. & J. O. Blanchette 2012. Nanoparticle and targeted systems for cancer therapy. *Advanced drug delivery reviews* **64**: 206-212.
- Brown, M. E. 2001. Introduction to Thermal Analysis: Techniques and Applications Ed.: Springer Netherlands.
- Cai, W., T. Gao, H. Hong & J. Sun 2008. Applications of gold nanoparticles in cancer nanotechnology. *Nanotechnology, Science and Applications* **1**: 17.
- Campbell, K. C., L. P. Rybak, R. P. Meech & L. Hughes 1996. D-methionine provides excellent protection from cisplatin cytotoxicity in the rat. *Hearing Research* **102**(1-2): 90-98.
- Cancer, I. A. f. R. O. 2012. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.
- Capek, I. 2017. Noble Metal Nanoparticles: Preparation, Composite Nanostructures, Biodecoration and Collective Properties Ed.: Springer Japan.
- Carmeliet, P. & R. K. Jain 2000. Angiogenesis in cancer and other diseases. *Nature* **407**(6801): 249-257.
- Castell, J. V. & M. J. Gmez-Lechn. 1996. In Vitro Methods in Pharmaceutical Research Ed.: Elsevier Science.
- Ceccarelli, E. A. & G. L. Rosano. 2014. Recombinant protein expression in microbial systems Ed.: Frontiers E-books.
- Chan, S., S. Kwon, T. W. Koo, L. P. Lee & A. A. Berlin 2003. Surface-Enhanced Raman Scattering of Small Molecules from Silver-Coated Silicon Nanopores. *Advanced Materials* **15**(19): 1595-1598.
- Chandran, S. P., M. Chaudhary, R. Pasricha, A. Ahmad & M. Sastry 2006. Synthesis of gold nanotriangles and silver nanoparticles using Aloe vera plant extract. *Biotechnology Progress* **22**(2): 577-583.
- Che, M. & J. C. Vedrine. 2012. Characterization of Solid Materials and Heterogeneous Catalysts: From Structure to Surface Reactivity Ed.: Wiley.
- Chen, T., Y. Liu, W.-J. Zheng, J. Liu & Y.-S. Wong 2010. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. *Inorganic Chemistry* **49**(14): 6366-6368.
- Cheng, Y. 2018. Polymeric Gene Delivery Systems Ed.: Springer International Publishing.

- Cheng, Z., H. Yang, L. Yu, Y. Cui & S. Feng 2006. Preparation and magnetic properties of $Y_3Fe_5O_{12}$ nanoparticles doped with the gadolinium oxide. *Journal of Magnetism and Magnetic Materials* **302**(1): 259-262.
- Chitkara, D., A. Mittal & R. I. Mahato. 2018. *Molecular Medicines for Cancer: Concepts and Applications of Nanotechnology* Ed.: CRC Press.
- Choi, O., K. K. Deng, N.-J. Kim, L. Ross Jr, R. Y. Surampalli & Z. Hu 2008. The inhibitory effects of silver nanoparticles, silver ions, and silver chloride colloids on microbial growth. *Water research* **42**(12): 3066-3074.
- Chu, E. & V. T. DeVita. 2006. *Physicians' cancer chemotherapy drug manual 2006* Ed.: Jones & Bartlett Learning.
- Chu, E. & V. T. DeVita. 2017. *Physicians' Cancer Chemotherapy Drug Manual 2018* Ed.: Jones & Bartlett Learning.
- Ciofani, G. 2018. *Smart Nanoparticles for Biomedicine* Ed.: Elsevier Science.
- Cohen, G. M. 1997. Caspases: the executioners of apoptosis. *Biochemical Journal* **326**(1): 1-16.
- Colditz, G. A. & C. J. Stein. 2004. *Handbook of Cancer Risk Assessment and Prevention* Ed.: Jones and Bartlett Publishers.
- Conde, J., G. Doria & P. Baptista 2012. Noble metal nanoparticles applications in cancer. *Journal of Drug Delivery* **2012**. Article ID 751075.
- Cory, S. & J. M. Adams 2002. The Bcl2 family: regulators of the cellular life-or-death switch. *Nature Reviews Cancer* **2**(9): 647-656.
- Couzin-Frankel, J. 2013. Cancer immunotherapy, American Association for the Advancement of Science. chrome-extension://oemmnrcbldboiebfnladdacbfmadadm/https://science.sciencemag.org/content/sci/342/6165/1432.full.pdf (Accessed on 16 June 2019).
- Cullen, K. J., Z. Yang, L. Schumaker & Z. Guo 2007. Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. *Journal of Bioenergetics and Biomembranes* **39**(1): 43-50.
- Cullity, B. D. & S. R. Stock. 2001. *Elements of X-ray Diffraction* Ed.: Prentice Hall.
- Da Silva, J. F. & R. J. P. Williams. 2001. *The biological chemistry of the elements: the inorganic chemistry of life* Ed.: Oxford University Press.
- Dabrowiak, J. C. 2013. *Metals in Medicine* Ed.: Wiley.
- Dalgleish, A. G. & M. J. Browning. 1996. *Tumor Immunology: Immunotherapy and Cancer Vaccines* Ed.: Cambridge University Press.

- Daniel, R., R. Ellis & B. C. H. Centre. 2001. *The Cancer Prevention Book: The Holistic Plan to Reduce Your Risk of Cancer and Revolutionize Your Life* Ed.: Simon & Schuster.
- Davies, R. L. & S. F. Etris 1997. The development and functions of silver in water purification and disease control. *Catalysis Today* **36**(1): 107-114.
- Davis, M. E. & D. M. Shin 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nature reviews Drug discovery* **7**(9): 771.
- de Crevoisier, R., S. L. Tucker, L. Dong, R. Mohan, R. Cheung, J. D. Cox & D. A. Kuban 2005. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. *International Journal of Radiation Oncology, Biology, Physics* **62**(4): 965-973.
- Deivaraj, T., N. L. Lala & J. Y. Lee 2005. Solvent-induced shape evolution of PVP protected spherical silver nanoparticles into triangular nanoplates and nanorods. *Journal of Colloid and Interface Science* **289**(2): 402-409.
- Dhawan, A. & S. Kwon. 2017. *In Vitro Toxicology* Ed.: Elsevier Science.
- Dizon, D. S., L. Krilov, E. Cohen, T. Gangadhar, P. A. Ganz, T. A. Hensing, S. Hunger, S. S. Krishnamurthi, A. B. Lassman & M. J. Markham 2016. Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **34**(9): 987-1013
- Doroshov, J. H. 2006. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. *Journal of the National Cancer Institute* **98**(4): 223-225.
- Driscoll, B. 2003. *Lung Cancer: Volume 1: Molecular Pathology Methods and Reviews* Ed.: Humana Press.
- Driscoll, B. 2003. *Lung Cancer: Volume 2: Diagnostic and Therapeutic Methods and Reviews* Ed.: Humana Press.
- Duzgunes, N. 2012. *Nanomedicine: Cancer, Diabetes, and Cardiovascular, Central Nervous System, Pulmonary and Inflammatory Diseases* Ed.: Elsevier Science.
- Earnest, C. M. & A. C. E.-O. T. Measurements. 1988. *Compositional Analysis by Thermogravimetry* Ed.: ASTM.
- El-Deiry, W. S. 2007. *Death Receptors in Cancer Therapy* Ed.: Humana Press.
- El-Sayed, I. H., X. Huang & M. A. El-Sayed 2005. Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold

nanoparticles in cancer diagnostics: applications in oral cancer. *Nano Letters* **5**(5): 829-834.

Elmore, S. 2007. Apoptosis: a review of programmed cell death. *Toxicologic pathology* **35**(4): 495-516.

Emily, H.-Y. C., M. C. Wei, S. Weiler, R. A. Flavell, T. W. Mak, T. Lindsten & S. J. Korsmeyer 2001. BCL-2, BCL-X L sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. *Molecular Cell* **8**(3): 705-711.

Engin, O. 2015. Colon Polyps and the Prevention of Colorectal Cancer Ed.: Springer International Publishing.

Eskes, R., S. Desagher, B. Antonsson & J.-C. Martinou 2000. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. *Molecular and Cellular Biology* **20**(3): 929-935.

Eustis, S. & M. A. El-Sayed 2006. Why gold nanoparticles are more precious than pretty gold: noble metal surface plasmon resonance and its enhancement of the radiative and nonradiative properties of nanocrystals of different shapes. *Chemical Society Reviews* **35**(3): 209-217.

Fawcett, W. R., A. A. Kloss & C. U. D. D. o. CHEMISTRY. 1996. Attenuated Total Reflection Fourier Transform Infrared Spectroscopic Study of Dimethyl Sulfoxide Self-Association in Acetonitrile Solutions Ed.: Defense Technical Information Center.

Florea, A.-M. & D. Büsselberg 2011. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. *Cancers* **3**(1): 1351-1371.

Focarete, M. & A. Tampieri. 2018. Core-Shell Nanostructures for Drug Delivery and Theranostics: Challenges, Strategies and Prospects for Novel Carrier Systems Ed.: Elsevier Science.

Foldbjerg, R., D. A. Dang & H. Autrup 2011. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. *Archives of Toxicology* **85**(7): 743-750.

Forrest, M. J. 2003. Analysis of Thermoset Materials, Precursors and Products Ed.: Rapra Technology Limited.

Fraga, C. G. 2005. Relevance, essentiality and toxicity of trace elements in human health. *Molecular Aspects of Medicine* **26**(4-5): 235-244.

Franks, L. M. & N. M. Teich. 1997. Introduction to the Cellular and Molecular Biology of Cancer Ed.: Oxford University Press.

- Fratila, R. M. & J. M. De La Fuente. 2018. *Nanomaterials for Magnetic and Optical Hyperthermia Applications* Ed.: Elsevier Science.
- Frazier, J. M. 1992. *In-Vitro Toxicity Testing: Applications to Safety Evaluation* Ed.: CRC Press.
- Fu, P. P., Q. Xia, H.-M. Hwang, P. C. Ray & H. Yu 2014. Mechanisms of nanotoxicity: generation of reactive oxygen species. *Journal of Food and Drug Analysis* **22**(1): 64-75.
- Gabbott, P. 2008. *Principles and Applications of Thermal Analysis* Ed.: Wiley.
- Gaiddon, C., P. Jeannequin, P. Bischoff, M. Pfeffer, C. Sirlin & J. Loeffler 2005. Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. *Journal of Pharmacology and Experimental Therapeutics* **315**(3): 1403-1411.
- Gao, W. 2001. *Study of Cytochrome C Release from Mitochondria During Apoptosis in Hela Cells* Ed.: Hong Kong University of Science and Technology.
- Gharagouzloo, C. A. 2016. *Quantitative Magnetic Resonance Imaging with Magnetic Nanoparticles* Ed.
- Ghosh, S. K., M. Mandal, S. Kundu, S. Nath & T. Pal 2004. Bimetallic Pt–Ni nanoparticles can catalyze reduction of aromatic nitro compounds by sodium borohydride in aqueous solution. *Applied Catalysis A: General* **268**(1-2): 61-66.
- Giljohann, D. A., D. S. Seferos, W. L. Daniel, M. D. Massich, P. C. Patel & C. A. Mirkin 2010. Gold nanoparticles for biology and medicine. *Angewandte Chemie International Edition* **49**(19): 3280-3294.
- Gnerlich, J., D. B. Jeffe, A. D. Deshpande, C. Beers, C. Zander & J. A. Margenthaler 2007. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. *Annals of Surgical Oncology* **14**(8): 2187-2194.
- Goldstein, J. I., D. E. Newbury, J. R. Michael, N. W. M. Ritchie, J. H. J. Scott & D. C. Joy. 2017. *Scanning Electron Microscopy and X-Ray Microanalysis* Ed.: Springer New York.
- Greeley, J., I. Stephens, A. Bondarenko, T. P. Johansson, H. A. Hansen, T. Jaramillo, J. Rossmeisl, I. Chorkendorff & J. K. Nørskov 2009. Alloys of platinum and early transition metals as oxygen reduction electrocatalysts. *Nature Chemistry* **1**(7): 552-556.

- Green, L. C., D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok & S. R. Tannenbaum 1982. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. *Analytical Biochemistry* **126**(1): 131-138.
- Grill, A. & D. A. Neumayer 2003. Structure of low dielectric constant to extreme low dielectric constant SiCOH films: Fourier transform infrared spectroscopy characterization. *Journal of Applied Physics* **94**(10): 6697-6707.
- Gross, A., J. M. McDonnell & S. J. Korsmeyer 1999. BCL-2 family members and the mitochondria in apoptosis. *Genes & Development* **13**(15): 1899-1911.
- Grumezescu, A. M. 2018. Drug Targeting and Stimuli Sensitive Drug Delivery Systems Ed.: Elsevier Science.
- Hadizadeh, S., N. Najafzadeh, M. Mazani, M. Amani, H. Mansouri-Torshizi & A. Niapour 2014. Cytotoxic effects of newly synthesized palladium (II) complexes of diethyldithiocarbamate on gastrointestinal cancer cell lines. *Biochemistry Research International* **2014**.
- Hagggar, F. A. & R. P. Boushey 2009. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clinics in Colon and Rectal Surgery* **22**(04): 191-197.
- Hamblin, M. R. & P. Avci. 2015. Applications of Nanoscience in Photomedicine Ed.: Elsevier Science.
- Hanada, M., C. Aimé-Sempé, T. Sato & J. C. Reed 1995. Structure-function analysis of Bcl-2 protein identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. *Journal of Biological Chemistry* **270**(20): 11962-11969.
- Hanahan, D. & R. A. Weinberg 2011. Hallmarks of cancer: the next generation. *Cell* **144**(5): 646-674.
- Haris, P. I. & D. Chapman 1992. Does Fourier-transform infrared spectroscopy provide useful information on protein structures? *Trends in Biochemical Sciences* **17**(9): 328-333.
- Hauert, R. 2003. A review of modified DLC coatings for biological applications. *Diamond and Related Materials* **12**(3-7): 583-589.
- Haycock, J., A. Ahluwalia & J. M. Wilkinson. 2014. Cellular In Vitro Testing: Methods and Protocols Ed.: Pan Stanford.
- Haynes, W. M. 2016. CRC Handbook of Chemistry and Physics, 97th Edition Ed.: CRC Press.
- Heide, J., W. Hinkelbein, A. Schmittl & D. Kaiser. 2010. Controversies in the Treatment of Lung Cancer Ed.: Karger.

- Heim, S. & F. Mitelman. 2011. *Cancer Cytogenetics: Chromosomal and Molecular Genetic Abberations of Tumor Cells* Ed.: Wiley.
- Herbst, R. S., P. Baas, D.-W. Kim, E. Felip, J. L. Pérez-Gracia, J.-Y. Han, J. Molina, J.-H. Kim, C. D. Arvis & M.-J. Ahn 2016. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *The Lancet* **387**(10027): 1540-1550.
- Hetz, C. 2011. *BCL-2 Protein Family: Essential Regulators of Cell Death* Ed.: Springer New York.
- Hill, S., D. Sarfati, T. Blakely, B. Robson, G. Purdie, E. Dennett, D. Cormack, K. Dew, J. Z. Ayanian & I. Kawachi 2010. Ethnicity and management of colon cancer in New Zealand. *Cancer* **116**(13): 3205-3214.
- Hirsch, L. R., R. J. Stafford, J. Bankson, S. R. Sershen, B. Rivera, R. Price, J. D. Hazle, N. J. Halas & J. L. West 2003. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. *Proceedings of the National Academy of Sciences* **100**(23): 13549-13554.
- Hockenbery, D. M. 2016. *Mitochondria and Cell Death* Ed.: Springer New York.
- Hong, W. K., A. A. f. C. Research, W. Hait, J. F. Holland, D. W. Kufe & R. E. Pollock. 2010. *Holland-Frei Cancer Medicine 8* Ed.: People's Medical Publishing House.
- Huaizhi, Z. & N. Yuantao 2000. Techniques used for the preparation and application of gold powder in ancient China. *Gold bulletin* **33**(3): 103-105.
- Huaizhi, Z. & N. Yuantao 2001. China's ancient gold drugs. *Gold Bulletin* **34**(1): 24-29.
- Huang, D. C. & A. Strasser 2000. BH3-only proteins—essential initiators of apoptotic cell death. *Cell* **103**(6): 839-842.
- Huang, L., M. C. Hung & E. Wagner. 2005. *Nonviral Vectors for Gene Therapy* Ed.: Elsevier Science.
- Huang, Q., F. Li, X. Liu, W. Li, W. Shi, F.-F. Liu, B. O'sullivan, Z. He, Y. Peng & A.-C. Tan 2011. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. *Nature Medicine* **17**(7): 860.
- Huang, X., I. H. El-Sayed, W. Qian & M. A. El-Sayed 2006. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. *Journal of the American Chemical Society* **128**(6): 2115-2120.
- Huang, X., P. K. Jain, I. H. El-Sayed & M. A. El-Sayed 2007. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. *Nanomedicine (Lond)* **2**(5): 681-693.

- Jaggi, O. P. 2005. Cancer: Causes, Prevention And Treatment Ed.: Orient Paperbacks.
- Jain, K. K. 2017. The Handbook of Nanomedicine Ed.: Springer New York.
- Jain, M., R. Nilsson, S. Sharma, N. Madhusudhan, T. Kitami, A. L. Souza, R. Kafri, M. W. Kirschner, C. B. Clish & V. K. Mootha 2012. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. *Science* **336**(6084): 1040-1044.
- Jain, P. K., X. Huang, I. H. El-Sayed & M. A. El-Sayed 2008. Noble metals on the nanoscale: optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. *Accounts of Chemical Research* **41**(12): 1578-1586.
- Jain, S., D. Hirst & J. O'sullivan 2014. Gold nanoparticles as novel agents for cancer therapy. *The British Journal of Radiology*.
- Jamieson, E. R. & S. J. Lippard 1999. Structure, recognition, and processing of cisplatin– DNA adducts. *Chemical Reviews* **99**(9): 2467-2498.
- Jensen, T. R., M. D. Malinsky, C. L. Haynes & R. P. Van Duyne 2000. Nanosphere lithography: tunable localized surface plasmon resonance spectra of silver nanoparticles. *The Journal of Physical Chemistry B* **104**(45): 10549-10556.
- Johnson, D. 2012. Cell Death Signaling in Cancer Biology and Treatment Ed.: Springer New York.
- Johnson, D. H., L. Fehrenbacher, W. F. Novotny, R. S. Herbst, J. J. Nemunaitis, D. M. Jablons, C. J. Langer, R. F. DeVore III, J. Gaudreault & L. A. Damico 2004. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *Journal of Clinical Oncology* **22**(11): 2184-2191.
- Kalinski, P. 2017. Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy Ed.: Springer International Publishing.
- Kalthoff, H. 2010. Death Receptors and Cognate Ligands in Cancer Ed.: Springer Berlin Heidelberg.
- Kavanagh, J. 1985. Sodium, potassium, calcium, magnesium, zinc, citrate and chloride content of human prostatic and seminal fluid. *Journal of Reproduction and Fertility* **75**(1): 35-41.
- Keservani, R. K. & A. K. Sharma. 2019. Nanoparticulate Drug Delivery Systems Ed.: Apple Academic Press.
- Kettleworth, C. R. 2007. Cell Apoptosis Research Advances Ed.: Nova Biomedical Books.

- Khosravi-Far, R., Z. Zakeri, R. A. Lockshin & M. Piacentini. 2008. Programmed Cell Death Ed.: Elsevier Science.
- Kim, G. J. & S. Nie 2005. Targeted cancer nanotherapy. *Materials Today* **8**(8): 28-33.
- Kittler, S., C. Greulich, J. Diendorf, M. Koller & M. Epple 2010. Toxicity of silver nanoparticles increases during storage because of slow dissolution under release of silver ions. *Chemistry of Materials* **22**(16): 4548-4554.
- Knowles, M. & P. Selby. 2005. Introduction to the Cellular and Molecular Biology of Cancer Ed.: OUP Oxford.
- Kröning, R., A. Lichtenstein & G. Nagami 2000. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. *Cancer Chemotherapy and Pharmacology* **45**(1): 43-49.
- Kubota, T., T. Egawa, Y. Otani, T. Furukawa, Y. Saikawa, M. Yoshida, M. Watanabe, K. Kumai & M. Kitajima 2003. Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination. *Anticancer Research* **23**(1B): 583-587.
- Kumar, C. S. S. R. 2010. Nanostructured Thin Films and Surfaces Ed.: John Wiley & Sons.
- Kumar, N. & S. Kumbhat. 2016. Essentials in Nanoscience and Nanotechnology Ed.: Wiley.
- Kumar, S. 2013. Apoptosis: Biology and Mechanisms Ed.: Springer Berlin Heidelberg.
- Kümmerle, M., S. Scherer & H. Seiler 1998. Rapid and reliable identification of food-borne yeasts by Fourier-transform infrared spectroscopy. *Applied and Environmental Microbiology* **64**(6): 2207-2214.
- Kuwana, T., L. Bouchier-Hayes, J. E. Chipuk, C. Bonzon, B. A. Sullivan, D. R. Green & D. D. Newmeyer 2005. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. *Molecular Cell* **17**(4): 525-535.
- Lacour, S., A. Hammann, S. Grazide, D. Lagadic-Gossmann, A. Athias, O. Sergent, G. Laurent, P. Gambert, E. Solary & M.-T. Dimanche-Boitrel 2004. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. *Cancer Research* **64**(10): 3593-3598.
- Lalley, J., D. D. Dionysiou, R. S. Varma, S. Shankara, D. J. Yang & M. N. Nadagouda 2014. Silver-based antibacterial surfaces for drinking water disinfection—an overview. *Current Opinion in Chemical Engineering* **3**: 25-29.

- Lamb, K. 2002. *Cancer Ed.: Raintree Steck-Vaughn.*
- Lancker, V. 2006. *Apoptosis, Genomic Integrity and Cancer Ed.: Jones & Bartlett Learning.*
- Larguinho, M. & P. V. Baptista 2012. Gold and silver nanoparticles for clinical diagnostics—from genomics to proteomics. *Journal of Proteomics* **75**(10): 2811-2823.
- Laurent, S., M. Mahmoudi & G. Korotcenkov. 2017. *Iron Oxide Nanoparticles for Biomedical Applications: Synthesis, Functionalization and Application Ed.: Elsevier Science.*
- Layek, K., R. Chakravarti, M. L. Kantam, H. Maheswaran & A. Vinu 2011. Nanocrystalline magnesium oxide stabilized gold nanoparticles: an advanced nanotechnology based recyclable heterogeneous catalyst platform for the one-pot synthesis of propargylamines. *Green Chemistry* **13**(10): 2878-2887.
- Layek, K., M. L. Kantam, M. Shirai, D. Nishio-Hamane, T. Sasaki & H. Maheswaran 2012. Gold nanoparticles stabilized on nanocrystalline magnesium oxide as an active catalyst for reduction of nitroarenes in aqueous medium at room temperature. *Green Chemistry* **14**(11): 3164-3174.
- Le Goff, A., V. Artero, B. Jusselme, P. D. Tran, N. Guillet, R. Métayé, A. Fihri, S. Palacin & M. Fontecave 2009. From hydrogenases to noble metal-free catalytic nanomaterials for H₂ production and uptake. *Science* **326**(5958): 1384-1387.
- Leemans, C. R., B. J. Braakhuis & R. H. Brakenhoff 2011. The molecular biology of head and neck cancer. *Nature Reviews Cancer* **11**(1): 9-22.
- Legato, M. J. 2009. *Principles of Gender-Specific Medicine Ed.: Elsevier Science.*
- Lehr, C. M. 2003. *Cell Culture Models of Biological Barriers: In vitro Test Systems for Drug Absorption and Delivery Ed.: CRC Press.*
- Lercher, J. A., C. Gründling & G. Eder-Mirth 1996. Infrared studies of the surface acidity of oxides and zeolites using adsorbed probe molecules. *Catalysis Today* **27**(3-4): 353-376.
- Liao, L., J. Liu, E. C. Dreaden, S. W. Morton, K. E. Shopsowitz, P. T. Hammond & J. A. Johnson 2014. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. *Journal of the American Chemical Society* **136**(16): 5896-5899.
- Liu, Z. & P. J. Sadler 2014. Organoiridium complexes: anticancer agents and catalysts. *Accounts of Chemical Research* **47**(4): 1174-1185.

- Loda, M., L. A. Mucci, M. L. Mittelstadt, M. Van Hemelrijck & M. B. Cotter. 2016. Pathology and Epidemiology of Cancer Ed.: Springer International Publishing.
- Loreto, C., G. La Rocca, R. Anzalone, R. Caltabiano, G. Vespasiani, S. Castorina, D. J. Ralph, S. Celtek, G. Musumeci & S. Giunta 2014. The role of intrinsic pathway in apoptosis activation and progression in Peyronie's disease. *BioMed Research International* **2014**.
- Los, M. & S. B. Gibson. 2006. Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases Ed.: Springer US.
- Lozano, G. & A. J. Levine. 2016. The P53 Protein: From Cell Regulation to Cancer Ed.: Cold Spring Harbor Laboratory Press.
- Lu, D. Y. 2014. Personalized Cancer Chemotherapy: An Effective Way of Enhancing Outcomes in Clinics Ed.: Elsevier Science.
- Lu, W. L. & X. R. Qi. 2020. Liposome-Based Drug Delivery Systems Ed.: Springer Berlin Heidelberg.
- Luo, X., I. Budihardjo, H. Zou, C. Slaughter & X. Wang 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. *Cell* **94**(4): 481-490.
- Lüth, H. 2013. Surfaces and interfaces of solid materials Ed.: Springer Science & Business Media.
- Lyden, D., D. R. Welch & B. Psaila. 2011. Cancer Metastasis: Biologic Basis and Therapeutics Ed.: Cambridge University Press.
- Lynch, J. 2003. Physico-chemical Analysis of Industrial Catalysts: A Practical Guide to Characterisation Ed.: Editions Technip.
- Macbeth, F., R. Milroy, W. Steward & R. Burnett. 1996. Lung Cancer Ed.: CRC Press.
- Macdonald, F., C. Ford & A. Casson. 2004. Molecular Biology of Cancer Ed.: Taylor & Francis.
- Makhlouf, A. S. H. & N. Y. Abu-Thabit. 2018. Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications: Volume 2: Advanced Nanocarriers for Therapeutics Ed.: Elsevier Science.
- Manikandan, M., N. Hasan & H.-F. Wu 2013. Platinum nanoparticles for the photothermal treatment of Neuro 2A cancer cells. *Biomaterials* **34**(23): 5833-5842.
- Marx, U. & V. Sandig. 2007. Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology Ed.: Wiley.

- Mathur, A. 2016. Nanotechnology in Cancer Ed.: Elsevier Science.
- Maulik, N. & T. Karagiannis. 2014. Molecular mechanisms and physiology of disease: Implications for Epigenetics and Health Ed.: Springer New York.
- Meijer, L., A. Jézéquel & B. Ducommun. 2012. Progress in Cell Cycle Research Ed.: Springer US.
- Melino, G. & D. Vaux. 2010. Cell Death Ed.: Wiley.
- Merchant, B. 1998. Gold, the noble metal and the paradoxes of its toxicology. *Biologicals* **26**(1): 49-59.
- Mftah, A., F. H. Alhassan, M. S. Al-Qubaisi, M. E. El Zowalaty, T. J. Webster, M. Sh-eldin, A. Rasedee, Y. H. Taufiq-Yap & S. S. Rashid 2015. Physicochemical properties, cytotoxicity, and antimicrobial activity of sulphated zirconia nanoparticles. *International Journal of Nanomedicine* **10**: 765.
- Micheau, O. 2017. TRAIL, Fas Ligand, TNF and TLR3 in Cancer Ed.: Springer International Publishing.
- Miethling-Graff, R., R. Rumpker, M. Richter, T. Verano-Braga, F. Kjeldsen, J. Brewer, J. Hoyland, H.-G. Rubahn & H. Erdmann 2014. Exposure to silver nanoparticles induces size- and dose-dependent oxidative stress and cytotoxicity in human colon carcinoma cells. *Toxicology In Vitro* **28**(7): 1280-1289.
- Mikhailov, V., M. Mikhailova, K. Degenhardt, M. A. Venkatachalam, E. White & P. Saikumar 2003. Association of Bax and Bak Homo-oligomers in mitochondria Bax requirement for Bak reorganization and cytochrome c release. *Journal of Biological Chemistry* **278**(7): 5367-5376.
- Mishra, A. K. 2013. Nanomedicine for Drug Delivery and Therapeutics Ed.: Wiley.
- Mishra, V., P. Kesharwani, M. C. I. M. Amin & A. Iyer. 2017. Nanotechnology-based approaches for targeting and delivery of drugs and genes Ed.: Elsevier Science.
- Mitsudomi, T., S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada & T. Hirashima 2010. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *The Lancet Oncology* **11**(2): 121-128.
- Mock, J., M. Barbic, D. Smith, D. Schultz & S. Schultz 2002. Shape effects in plasmon resonance of individual colloidal silver nanoparticles. *The Journal of Chemical Physics* **116**(15): 6755-6759.

- Moore, E. 2016. Fourier Transform Infrared Spectroscopy (FTIR): Methods, Analysis and Research Insights Ed.: Nova Science Publishers, Incorporated.
- Mor, G. & A. Alvero. 2007. Apoptosis and Cancer: Methods and Protocols Ed.: Humana Press.
- Motoyama, N., F. Wang, K. A. Roth, H. Sawa, K.-i. Nakayama, I. Negishi, S. Senju, Q. Zhang & S. Fujii 1995. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. *Science* **267**(5203): 1506-1510.
- Muhammad, N. & Z. Guo 2014. Metal-based anticancer chemotherapeutic agents. *Current Opinion in Chemical Biology* **19**: 144-153.
- Mulfinger, L., S. D. Solomon, M. Bahadory, A. V. Jeyarajasingam, S. A. Rutkowsky & C. Boritz 2007. Synthesis and study of silver nanoparticles. *Journal of Chemical Education* **84**(2): 322.
- Nejdl, L., J. Kudr, A. Moulick, D. Hegerova, B. Ruttkay-Nedecky, J. Gumulec, K. Cihalova, K. Smerkova, S. Dostalova & S. Krizkova 2017. Platinum nanoparticles induce damage to DNA and inhibit DNA replication. *PLoS ONE* **12**(7): e0180798.
- Nichols, J. W. & Y. H. Bae 2012. Odyssey of a cancer nanoparticle: from injection site to site of action. *Nano Today* **7**(6): 606-618.
- Nicholson, D. W. & N. A. Thornberry 1997. Caspases: killer proteases. *Trends in Biochemical Sciences* **22**(8): 299-306.
- Nie, S., Y. Xing, G. J. Kim & J. W. Simons 2007. Nanotechnology applications in cancer. *Annual Review of Biomedical Engineering* **9**: 257-288.
- Nomori, H. & M. Okada. 2012. Illustrated Anatomical Segmentectomy for Lung Cancer Ed.: Springer Japan.
- Nordberg, G. F., B. A. Fowler & M. Nordberg. 2014. Handbook on the Toxicology of Metals Ed.: Academic Press.
- Nundy, S. 2010. Stay Healthy at Every Age: What Your Doctor Wants You to Know Ed.: Johns Hopkins University Press.
- O'Brien, P., V. S. Coker, M. Green & S. Corr. 2012. Nanoscience: Nanostructures Through Chemistry Ed.: Royal Society of Chemistry.
- Oberg, K. A. & A. L. Fink 1998. A new attenuated total reflectance Fourier transform infrared spectroscopy method for the study of proteins in solution. *Analytical Biochemistry* **256**(1): 92-106.
- Orrenius, S., V. Gogvadze & B. Zhivotovsky 2015. Calcium and mitochondria in the regulation of cell death. *Biochemical and Biophysical Research Communications* **460**(1): 72-81.

- Özdemir, Y. G., S. B. Pehlivan & E. Sekerdag. 2017. Nanotechnology Methods for Neurological Diseases and Brain Tumors: Drug Delivery across the Blood–Brain Barrier Ed.: Elsevier Science.
- Palma, D. & A. Zietman. 2017. Taking Charge of Cancer: What You Need to Know to Get the Best Treatment Ed.: New Harbinger Publications.
- Pan, D. 2014. Nanomedicine: A Soft Matter Perspective Ed.: CRC Press.
- Pandya, K. J., J. R. Brahmer & M. Hidalgo. 2016. Lung Cancer: Translational and Emerging Therapies Ed.: CRC Press.
- Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. *Nature Reviews Cancer* **12**(4): 252.
- Pathak, Y. V. 2019. Surface Modification of Nanoparticles for Targeted Drug Delivery Ed.: Springer.
- Patterson, A. 1939. The Scherrer formula for X-ray particle size determination. *Physical Review* **56**(10): 978.
- Pecorino, L. 2012. Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics Ed.: OUP Oxford.
- Pernicova, I. & M. Korbonits 2014. Metformin [mdash] mode of action and clinical implications for diabetes and cancer. *Nature Reviews Endocrinology* **10**(3): 143-156.
- Perry, M. C. 2008. The chemotherapy source book Ed.: Lippincott Williams & Wilkins.
- Piao, M. J., K. A. Kang, I. K. Lee, H. S. Kim, S. Kim, J. Y. Choi, J. Choi & J. W. Hyun 2011. Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis. *Toxicology Letters* **201**(1): 92-100.
- Pillai, Z. S. & P. V. Kamat 2004. What factors control the size and shape of silver nanoparticles in the citrate ion reduction method? *The Journal of Physical Chemistry B* **108**(3): 945-951.
- Popat, K. 2010. Nanotechnology in Tissue Engineering and Regenerative Medicine Ed.: CRC Press.
- Potten, C. & J. Wilson. 2004. Apoptosis: The Life and Death of Cells Ed.: Cambridge University Press.
- Prabhu, D., C. Arulvasu, G. Babu, R. Manikandan & P. Srinivasan 2013. Biologically synthesized green silver nanoparticles from leaf extract of *Vitex negundo* L. induce growth-inhibitory effect on human colon cancer cell line HCT15. *Process Biochemistry* **48**(2): 317-324.

- Pranczk, J., D. Jacewicz, D. Wyrzykowski & L. Chmurzynski 2014. Platinum (II) and palladium (II) complex compounds as anti-cancer drugs. Methods of cytotoxicity determination. *Current Pharmaceutical Analysis* **10**(1): 2-9.
- Prasad, P. N. 2012. Introduction to Nanomedicine and Nanobioengineering Ed.: Wiley.
- Prestayko, A. W. 2013. Cisplatin: Current Status and New Developments Ed.: Elsevier Science.
- Prokop, A. 2011. Intracellular Delivery: Fundamentals and Applications Ed.: Springer Netherlands.
- Rai, M. & R. Shegokar. 2017. Metal Nanoparticles in Pharma Ed.: Springer International Publishing.
- Reckamp, K. L. 2016. Lung Cancer: Treatment and Research Ed.: Springer International Publishing.
- Reed, J. C. & D. R. Green. 2011. Apoptosis: Physiology and Pathology Ed.: Cambridge University Press.
- Rees, O. J. 2010. Fourier Transform Infrared Spectroscopy: Developments, Techniques, and Applications Ed.: Nova Science Publishers.
- Reifferscheid, G. & S. Buchinger. 2017. In vitro Environmental Toxicology - Concepts, Application and Assessment Ed.: Springer International Publishing.
- Renard, P. E. L. 2011. Injectable formulations forming an implant in situ as vehicle of silica microparticles embedding superparamagnetic iron oxide nanoparticles for the local, magnetically mediated hyperthermia treatment of solid tumors Ed.: éditeur non identifié. <https://archive-ouverte.unige.ch/unige:21604> (Accessed on 16 June 2019)
- Robinson, R. L., D. H. Gwo & R. J. Saykally 1987. The high-resolution far infrared spectrum of a van der Waals stretching vibration: The ν_3 band of Ar-HCl. *The Journal of Chemical Physics* **87**(9): 5156-5160.
- Rodriguez-Bigas, M. A., R. Cutait, P. M. Lynch, I. Tomlinson & H. F. A. Vasen. 2010. Hereditary Colorectal Cancer Ed.: Springer US.
- Rodriguez, J. M., M. A. Glozak, Y. Ma & W. D. Cress 2006. Bok, Bcl-2-related ovarian killer, is cell cycle-regulated and sensitizes to stress-induced apoptosis. *Journal of Biological Chemistry* **281**(32): 22729-22735.
- Rosell, R., K. D. Danenberg, V. Alberola, G. Bepler, J. J. Sanchez, C. Camps, M. Provencio, D. Isla, M. Taron & P. Diz 2004. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated

advanced non-small cell lung cancer patients. *Clinical Cancer Research* **10**(4): 1318-1325.

Roth, J. A., J. D. Cox & W. K. Hong. 2011. Lung Cancer Ed.: Wiley.

Ruddon, R. 2010. Molecular Biology of Cancer: Translation to the Clinic Ed.: Elsevier Science.

Ruffolo, R. R. & F. Walsh. 2003. Apoptosis in Health and Disease Ed.: CRC Press.

Russ, J. C., M. A. Frs, R. Kiessling & J. Charles. 2013. Fundamentals of Energy Dispersive X-Ray Analysis: Butterworths Monographs in Materials Ed.: Elsevier Science.

Russell, J. & R. Cohn. 2012. Thermogravimetric Analysis Ed.: Book on Demand.

Saltz, L. B. 2007. Colorectal Cancer: Evidence-based Chemotherapy Strategies Ed.: Humana Press.

Sandler, A., R. Gray, M. C. Perry, J. Brahmer, J. H. Schiller, A. Dowlati, R. Lilenbaum & D. H. Johnson 2006. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *New England Journal of Medicine* **355**(24): 2542-2550.

Sanna, V., N. Pala & M. Sechi 2014. Targeted therapy using nanotechnology: focus on cancer. *International Journal of Nanomedicine* **9**: 467-483.

Satapathy, S. R., P. Mohapatra, R. Preet, D. Das, B. Sarkar, T. Choudhuri, M. D. Wyatt & C. N. Kundu 2013. Silver-based nanoparticles induce apoptosis in human colon cancer cells mediated through p53. *Nanomedicine* **8**(8): 1307-1322.

Sau, T. K., A. L. Rogach, F. Jäckel, T. A. Klar & J. Feldmann 2010. Properties and applications of colloidal nonspherical noble metal nanoparticles. *Advanced Materials* **22**(16): 1805-1825.

Schäfer-Korting, M. 2010. Drug Delivery Ed.: Springer Berlin Heidelberg.

Schor, N. & C. S. H. O. P. PA. 2000. Exploiting Bcl-2 Overexpression in the Chemotherapy of Breast Cancer Ed.: Defense Technical Information Center.

Seddon, B. & P. Workman 2014. The role of functional and molecular imaging in cancer drug discovery and development. *The British Journal of Radiology*.

Seeck, O. H. & B. Murphy. 2015. X-Ray Diffraction: Modern Experimental Techniques Ed.: Pan Stanford Publishing.

Shankar, S. S., A. Rai, A. Ahmad & M. Sastry 2004. Rapid synthesis of Au, Ag, and bimetallic Au core-Ag shell nanoparticles using Neem (*Azadirachta indica*) leaf broth. *Journal of Colloid and Interface Science* **275**(2): 496-502.

- Sharma, H. S., D. F. Muresanu & A. Sharma. 2017. Drug and Gene Delivery to the Central Nervous System for Neuroprotection: Nanotechnological Advances Ed.: Springer International Publishing.
- Shi, Y. & F. B. Hu 2014. The global implications of diabetes and cancer. *The Lancet* **383**(9933): 1947-1948.
- Shin, H. S., H. J. Yang, S. B. Kim & M. S. Lee 2004. Mechanism of growth of colloidal silver nanoparticles stabilized by polyvinyl pyrrolidone in γ -irradiated silver nitrate solution. *Journal of Colloid and Interface Science* **274**(1): 89-94.
- Shindo, D. & T. Oikawa. 2013. Analytical Electron Microscopy for Materials Science Ed.: Springer Japan.
- Shrivastava, D. 2018. Theory and Applications of Heat Transfer in Humans Ed.: Wiley.
- Shultz, L. B. 2007. Cell Apoptosis: Regulation and Environmental Factors Ed.: Nova Biomedical Books.
- Siddik, Z. H. 2010. Checkpoint Controls and Targets in Cancer Therapy Ed.: Humana Press.
- Siegel, R., J. Ma, Z. Zou & A. Jemal 2014. Cancer statistics, 2014. *CA: A Cancer Journal for Clinicians* **64**(1): 9-29.
- Siegel, R., D. Naishadham & A. Jemal 2013. Cancer statistics, 2013. *CA: A Cancer Journal for Clinicians* **63**(1): 11-30.
- Siegel, R. L., K. D. Miller & A. Jemal 2016. Cancer statistics, 2016. *CA: A Cancer Journal for Clinicians* **66**(1): 7-30.
- Sigel, H. 1983. Metal ions in biological systems: volume 15: zinc and its role in biology and nutrition Ed. 15. CRC press.
- Silverstein, A., V. B. Silverstein & L. S. Nunn. 2006. Cancer: Conquering a Deadly Disease Ed.: Twenty-First Century Books.
- Skeel, R. T. & S. N. Khleif. 2011. Handbook of Cancer Chemotherapy Ed.: Lippincott Williams & Wilkins.
- Sluysers, M. 2005. Application of Apoptosis to Cancer Treatment Ed.: Springer.
- Smith, B. C. 2011. Fundamentals of Fourier Transform Infrared Spectroscopy, Second Edition Ed.: CRC Press.
- Soni, S. 2014. Handbook of Research on Diverse Applications of Nanotechnology in Biomedicine, Chemistry, and Engineering Ed.: IGI Global.

- Sönnichsen, C., B. M. Reinhard, J. Liphardt & A. P. Alivisatos 2005. A molecular ruler based on plasmon coupling of single gold and silver nanoparticles. *Nature Biotechnology* **23**(6): 741.
- Sriram, M. I., S. B. M. Kanth, K. Kalishwaralal & S. Gurunathan 2010. Antitumor activity of silver nanoparticles in Dalton's lymphoma ascites tumor model. *International Journal of Nanomedicine* **5**: 753.
- Srivastava, R. 2007. Apoptosis, Cell Signaling, and Human Diseases: Molecular Mechanisms Ed.: Humana Press.
- Srivastava, S., D. E. Henson & A. F. Gazdar. 1999. Molecular Pathology of Early Cancer Ed.: IOS Press.
- Stein, G. S. & A. B. Pardee. 2004. Cell Cycle and Growth Control: Biomolecular Regulation and Cancer Ed.: Wiley.
- Stern, S., D. Dierdorf & A. R. A. I. T. FL. 2005. Thermogravimetric Analysis (TGA) of Various Epoxy Composite Formulations Ed.: Defense Technical Information Center.
- Stewart, B. & C. P. Wild 2017. World cancer report 2014. chrome-extension://oemmnrcbldboiebfnladdacbfmadadm/https://www.drugsandalcohol.ie/28525/1/World%20Cancer%20Report.pdf (Accessed on 16 June 2019)
- Stewart, N. G. 1998. P53 control over cell cycle progression at G2.
- Suelter, C. 1974. Monovalent cations in enzyme-catalyzed reactions. *Metal Ions in Biological Systems* **3**: 201-251.
- Sullenger, D., J. Cantrell, T. Beiter & D. Tomlin. 1996. Quality experimental and calculated powder x-ray diffraction. chrome-extension://oemmnrcbldboiebfnladdacbfmadadm/https://digital.library.unt.edu/ark:/67531/metadc670027/m2/1/high_res_d/274162.pdf (Accessed on 16 June 2019)
- Sun, X. & Y. Li 2004. Colloidal carbon spheres and their core/shell structures with noble-metal nanoparticles. *Angewandte Chemie* **116**(5): 607-611.
- Sun, Y., B. Mayers & Y. Xia 2003. Transformation of silver nanospheres into nanobelts and triangular nanoplates through a thermal process. *Nano Letters* **3**(5): 675-679.
- Sun, Y. & Y. Xia 2002. Shape-controlled synthesis of gold and silver nanoparticles. *Science* **298**(5601): 2176-2179.
- Surhone, L. M., M. T. Timpledon & S. F. Marseken. 2010. Thermogravimetric Analysis Ed.: VDM Publishing.

- Suryanarayana, C. & M. G. Norton. 2013. X-Ray Diffraction: A Practical Approach Ed.: Springer US.
- Testa, J. R. 2017. Asbestos and Mesothelioma Ed.: Springer International Publishing.
- Thanh, N. T. K. 2012. Magnetic Nanoparticles: From Fabrication to Clinical Applications Ed.: Taylor & Francis.
- Thanh, N. T. K. 2018. Clinical Applications of Magnetic Nanoparticles Ed.: CRC Press.
- Thanh, N. T. K. 2018. Clinical Applications of Magnetic Nanoparticles: From Fabrication to Clinical Applications Ed.: CRC Press.
- Thomas-Tikhonenko, A. 2010. Cancer Genome and Tumor Microenvironment Ed.: Springer New York.
- Thompson, K. H. & C. Orvig 2003. Boon and bane of metal ions in medicine. *Science* **300**(5621): 936-939.
- Tibbals, H. F. 2017. Medical Nanotechnology and Nanomedicine Ed.: CRC Press.
- Tomitaka, A., T. Yamada & Y. Takemura 2012. Magnetic nanoparticle hyperthermia using pluronic-coated Fe₃O₄ nanoparticles: an in vitro study. *Journal of Nanomaterials* **2012**: 4.
- Torre, L. A., R. L. Siegel, E. M. Ward & A. Jemal 2016. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiology and Prevention Biomarkers* **25**(1): 16-27.
- Trondl, R., P. Heffeter, C. R. Kowol, M. A. Jakupec, W. Berger & B. K. Keppler 2014. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. *Chemical Science* **5**:2925-2932.
- Tsuji, K., J. Injuk & R. Van Grieken. 2005. X-Ray Spectrometry: Recent Technological Advances Ed.: Wiley.
- Turner, M., V. B. Golovko, O. P. Vaughan, P. Abdulkin, A. Berenguer-Murcia, M. S. Tikhov, B. F. Johnson & R. M. Lambert 2008. Selective oxidation with dioxygen by gold nanoparticle catalysts derived from 55-atom clusters. *Nature* **454**(7207): 981-983.
- van Rijt, S. H. & P. J. Sadler 2009. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. *Drug Discovery Today* **14**(23): 1089-1097.
- Vande Woude, G. F. & G. Klein. 2002. Advances in Cancer Research Ed.: Elsevier Science.

- Varadan, V. K., L. F. Chen & J. Xie. 2008. *Nanomedicine: Design and Applications of Magnetic Nanomaterials, Nanosensors and Nanosystems* Ed.: Wiley.
- Vermeulen, M., H. C. Eberl, F. Matarese, H. Marks, S. Denissov, F. Butter, K. K. Lee, J. V. Olsen, A. A. Hyman & H. G. Stunnenberg 2010. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. *Cell* **142**(6): 967-980.
- Virkutyte, J. & R. S. Varma 2011. Green synthesis of metal nanoparticles: biodegradable polymers and enzymes in stabilization and surface functionalization. *Chemical Science* **2**(5): 837-846.
- Wajant, H., J. Gerspach & K. Pfizenmaier 2005. Tumor therapeutics by design: targeting and activation of death receptors. *Cytokine & Growth Factor Reviews* **16**(1): 55-76.
- Wang, A. Z., R. Langer & O. C. Farokhzad 2012. Nanoparticle delivery of cancer drugs. *Annual Review of Medicine* **63**: 185-198.
- Wang, K., X.-M. Yin, D. T. Chao, C. L. Milliman & S. J. Korsmeyer 1996. BID: a novel BH3 domain-only death agonist. *Genes & Development* **10**(22): 2859-2869.
- Wang, Y., Z. Li, J. Wang, J. Li & Y. Lin 2011. Graphene and graphene oxide: biofunctionalization and applications in biotechnology. *Trends in Biotechnology* **29**(5): 205-212.
- Warren, B. E. 2012. *X-Ray Diffraction* Ed.: Dover Publications.
- Warren, J. 2016. *Caspases: Roles and Significance in Cell Death and Disease* Ed.: Nova Science Publishers, Incorporated.
- Watters, D. & M. Lavin. 2003. *Signalling Pathways in Apoptosis* Ed.: Taylor & Francis.
- Wei, L., J. Lu, H. Xu, A. Patel, Z.-S. Chen & G. Chen 2015. Silver nanoparticles: synthesis, properties, and therapeutic applications. *Drug Discovery Today* **20**(5): 595-601.
- Weinstein, J. N., E. A. Collisson, G. B. Mills, K. R. M. Shaw, B. A. Ozenberger, K. Ellrott, I. Shmulevich, C. Sander, J. M. Stuart & C. G. A. R. Network 2013. The cancer genome atlas pan-cancer analysis project. *Nature Genetics* **45**(10): 1113-1120.
- West, A. R. 2014. *Solid state chemistry and its applications* Ed.: Wiley.
- West, N. P., E. J. Morris, O. Rotimi, A. Cairns, P. J. Finan & P. Quirke 2008. Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. *The lancet oncology* **9**(9): 857-865.

- Willis, S. N. & J. M. Adams 2005. Life in the balance: how BH3-only proteins induce apoptosis. *Current Opinion in Cell Biology* **17**(6): 617-625.
- Wu, H. 2013. *Cell Death: Mechanism and Disease* Ed.: Springer New York.
- Wyrobek, A. J., T. E. Schmid & F. Marchetti 2005. Relative susceptibilities of male germ cells to genetic defects induced by cancer chemotherapies. *JNCI Monographs* **2005**(34): 31-35.
- Xu, H., Q. Li, L. Wang, Y. He, J. Shi, B. Tang & C. Fan 2014. Nanoscale optical probes for cellular imaging. *Chemical Society Reviews* **43**(8): 2650-2661.
- Yamamoto, A., R. Honma & M. Sumita 1998. Cytotoxicity evaluation of 43 metal salts using murine fibroblasts and osteoblastic cells. *Journal of Biomedical Materials Research: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and the Australian Society for Biomaterials* **39**(2): 331-340.
- Yang, W., P. J. Weng & Y. Gao 2016. A new paradigm of DNA synthesis: three-metal-ion catalysis. *Cell & Bioscience* **6**(1): 51.
- Yin, X.-M., Z. N. Oltvai & S. J. Korsmeyer 1994. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. *Nature* **369**(6478): 321-323.
- Yin, X. M. & Z. Dong. 2009. *Essentials of Apoptosis: A Guide for Basic and Clinical Research* Ed.: Humana Press.
- Youle, R. J. & A. Strasser 2008. The BCL-2 protein family: opposing activities that mediate cell death. *Nature Reviews Molecular Cell Biology* **9**(1): 47-59.
- Young, A. M., R. Hobbs & D. J. Kerr. 2011. *ABC of Colorectal Cancer* Ed.: Wiley.
- Yousef, G. M. & S. Jothy. 2014. *Molecular Testing in Cancer* Ed.: Springer New York.
- Zachariasen, W. H. 2004. *Theory of X-ray Diffraction in Crystals* Ed.: Courier Corporation.
- Zhang, C. X. & S. J. Lippard 2003. New metal complexes as potential therapeutics. *Current Opinion in Chemical Biology* **7**(4): 481-489.
- Zhen, X., X. Wang, C. Xie, W. Wu & X. Jiang 2013. Cellular uptake, antitumor response and tumor penetration of cisplatin-loaded milk protein nanoparticles. *Biomaterials* **34**(4): 1372-1382.
- Zhou, M., Z. Wei, H. Qiao, L. Zhu, H. Yang & T. Xia 2009. Particle size and pore structure characterization of silver nanoparticles prepared by confined arc plasma. *Journal of Nanomaterials* **2009**: 3.

Zhu, B., K. Qiu, C. Shang & Z. Guo 2015. Naturally derived porous carbon with selective metal-and/or nitrogen-doping for efficient CO₂ capture and oxygen reduction. *Journal of Materials Chemistry A* **3**(9): 5212-5222.

Zinkel, S., A. Gross & E. Yang 2006. BCL2 family in DNA damage and cell cycle control. *Cell Death & Differentiation* **13**(8): 1351-1359.

Zuberek, M., D. Wojciechowska, D. Krzyzanowski, S. Meczynska-Wielgosz, M. Kruszewski & A. Grzelak 2015. Glucose availability determines silver nanoparticles toxicity in HepG2. *Journal of Nanobiotechnology* **13**(1): 72.



BIODATA OF STUDENT

Mohamed Q. Khlaif Al-Fahdawi was born on 9th April 1983 in Ramadi, the provincial capital of Al-Anbar, Iraq. He is the 1st child in his family. He received his primary education in Aghadeer School in Khaldiyyah and continued his secondary schooling at Palestine School in Ramadi, Al-Anbar. Then he pursued his study in Department of Biological sciences, Faculty of Science, Al-Anbar University from 2004 to 2008. After the completion of his Bachelor, he worked as a medical laboratory technician in Khaldiyyah Hospital, Iraq, from 2009 to now. In September 2014, he started his Master studies in the field of Medical Biotechnology working on formulation of two different metallic nanoparticles on various cancer cell lines. In October 2016, he started his PhD studies in the field of Nanomedicine working on formulation of three different Noble nanoparticles on various cancer cell lines.



LIST OF PUBLICATIONS

Journal Paper

Al-Fahdawi, M., Rasedee, A., Alhassan, F. H., Al-Qubaisi, M. S., Rosli, R., El Zowalaty, M. E.,Taufiq-Yap, Y. H. (2015). Cytotoxicity and physicochemical characterization of palladium magnesia nanoparticles. *Future Medicine: Nanomedicine. In press.*

Al-Fahdawi, M., Rasedee, A., Alhassan, F. H., Al-Qubaisi, M. S., Rosli, R., El Zowalaty, M. E.,Taufiq-Yap, Y. H. Cytotoxicity and physicochemical characterization of silver magnesia nanoparticles. *Drug Design, Development and Treatment. . In press.*

Al-Fahdawi, M., Rasedee, A., Alhassan, F. H., Al-Qubaisi, M. S., Rosli, R., El Zowalaty, M. E.,Taufiq-Yap, Y. H. (2015). Cytotoxicity and physicochemical characterization of platinum magnesia nanoparticles. Submitted to *International Journal of Nanomedicine.*



UNIVERSITI PUTRA MALAYSIA

STATUS CONFIRMATION FOR THESIS / PROJECT REPORT AND COPYRIGHT

ACADEMIC SESSION : Second Semester 2018/2019

TITLE OF THESIS / PROJECT REPORT :

PHYSICOCHEMICAL CHARACTERIZATION OF PALLADIUM-, PLATINUM-, SILVER-DOPED MAGNESIA NANOPARTICLES AND *IN VITRO* CYTOTOXICITY IN A549 (LUNG) AND HT29 (COLON) CANCER CELL LINES

NAME OF STUDENT: MOHAMMED QASIM KHLAIF

I acknowledge that the copyright and other intellectual property in the thesis/project report belonged to Universiti Putra Malaysia and I agree to allow this thesis/project report to be placed at the library under the following terms:

1. This thesis/project report is the property of Universiti Putra Malaysia.
2. The library of Universiti Putra Malaysia has the right to make copies for educational purposes only.
3. The library of Universiti Putra Malaysia is allowed to make copies of this thesis for academic exchange.

I declare that this thesis is classified as :

*Please tick (✓)

CONFIDENTIAL

(Contain confidential information under Official Secret Act 1972).

RESTRICTED

(Contains restricted information as specified by the organization/institution where research was done).

OPEN ACCESS

I agree that my thesis/project report to be published as hard copy or online open access.

This thesis is submitted for :

PATENT

Embargo from _____ until _____
(date) (date)

Approved by:

(Signature of Student)
New IC No/ Passport No.:

Date :

(Signature of Chairman of Supervisory Committee)
Name:

Date :

[Note : If the thesis is CONFIDENTIAL or RESTRICTED, please attach with the letter from the organization/institution with period and reasons for confidentially or restricted.]